Oslo University Hospital HF

Haematology and Cellular Immunotherapy

Research activity includes follicular lymphoma, multiple myeloma, acute lymphoblastic leukemia, lymphoblastic lymphoma, and graft-versus-host disease, with a strong interest in targeted immune-based treatment strategies and disease monitoring in blood cancers.

  • Follicular lymphoma
  • Multiple myeloma
  • Acute lymphoblastic leukemia
  • Graft-versus-host disease

Additional work spans minimal residual disease-guided treatment, CAR T-cell therapy, and vaccine-based immunotherapy in relapsed or high-risk haematological malignancies.

Solid Tumours and Precision Oncology

The sponsor is active in breast cancer, non-small cell lung cancer, glioblastoma, colorectal cancer, melanoma, esophageal cancer, pancreatic cancer, and malignant pleural mesothelioma, with emphasis on biomarker-informed treatment selection and tumour-directed immunotherapy.

  • Breast cancer
  • Non-small cell lung cancer
  • Glioblastoma
  • Colorectal cancer
  • Melanoma

Clinical interests also include molecularly selected therapy, neoadjuvant treatment, radiotherapy combinations, and personalized tumour profiling.

Neurology, Stroke, and Cognitive Disorders

Trials address acute ischemic stroke, multiple sclerosis, amyotrophic lateral sclerosis, migraine, cognitive impairment, delirium, and autism spectrum disorder, reflecting sustained interest in neurological function, neuroprotection, and symptom control.

  • Acute ischemic stroke
  • Multiple sclerosis
  • Amyotrophic lateral sclerosis
  • Chronic migraine
  • Delirium

Work in this area also covers neural plasticity, post-stroke recovery, and treatment of brain metastases and other central nervous system conditions.

Cardiovascular, Transplantation, and Perioperative Care

Research spans aortic stenosis, arrhythmic mitral valve prolapse, heart transplant, kidney transplantation, kidney failure, and univentricular congenital heart disease, with attention to graft function, rhythm disorders, and cardiovascular support.

  • Aortic stenosis
  • Heart transplant
  • Kidney transplantation
  • Arrhythmic mitral valve prolapse
  • Kidney failure

Additional themes include anticoagulation, hemodynamic management, postoperative delirium, and renal protection in transplant recipients.

Inflammatory, Rare, and Organ-Specific Diseases

The portfolio includes primary sclerosing cholangitis, juvenile idiopathic arthritis, granulomatous lymphocytic interstitial lung disease, venous malformation, frontal fibrosing alopecia, keratolytic winter erythema, and hydrocephalus, showing interest in rare and organ-specific disorders.

  • Primary sclerosing cholangitis
  • Juvenile idiopathic arthritis
  • Granulomatous lymphocytic interstitial lung disease
  • Venous malformation
  • Hydrocephalus

Other areas include ophthalmology, orthopaedics, infectious diseases, and maternal and neonatal care, alongside studies of pain and functional recovery.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • Study on Enalapril for Adults with Painful Venous Malformations

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Study on the Effectiveness of Floxuridine with Gemcitabine and Oxaliplatin for Patients with Intra-hepatic Cholangiocarcinoma Not Suitable for Surgery

    Recruiting

    3 1 1 1
    Norway
  • Study on the Effect and Safety of Flecainide and Metoprolol for Patients with Arrhythmic Mitral Valve Prolapse

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Study on Nepafenac and Dexamethasone for Reducing Inflammation and Swelling in Fuchs Dystrophy Patients After Corneal Transplant

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Study on Gemcitabine for Patients with Recurrent Glioblastoma

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway
  • Phase II study of sirolimus in patients with vascular malformation undergoing surgery and laser therapy to assess long‑term reduction of port‑wine macrocheilia volume

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Norway